Navigation Links
Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
Date:1/18/2011

PRINCETON, N.J., Jan. 18, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, announced today promising preliminary results from a preclinical study of SGX202 (oral beclomathasone dipropionate or BDP) in a canine gastrointestinal acute radiation syndrome (GARS) model. The results indicate that dogs treated with SGX202 demonstrated statistically significant (p=0.04) improvement in survival after exposure to lethal doses of total body irradiation (TBI) when compared to control dogs.

These results demonstrate that SGX202 has the potential to reduce the inflammatory cytokine storm induced by the radiation damaged gastrointestinal (Gl) tract. The GI tract is extremely sensitive to radiation injury. GI damage is the major cause of rapid mortality during high dose radiation exposure, such as could be encountered during nuclear accidents or with the use of dirty bombs. Gut injury from high dose radiation is associated with epithelial cell damage and hypoperfusion of the intestine, which stimulates a vigorous local and systemic inflammatory response.

The aim of the study was to determine whether SGX202 could improve survival and GI recovery after TBI using a well-established GARS dog model. Six dogs were exposed to TBI (12 Gy administered at 70 cGy/min), and then given autologous bone marrow and SGX202 with supportive care; four dogs were used as controls and not treated with SGX202.  Autologous bone marrow was given to reduce the duration and impact of the radiation-induced hematopoietic syndrome and allow for a focus on measures to treat the GI effects of TBI. SGX202 was administered two hours after TBI and daily until GI recovery (up to day 100 post exposure).  Median survival post exposure in the control group was 8 days, compared to greater than 100 days in the SGX202 treat
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
2. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
3. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
4. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
5. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
6. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
7. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
8. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
9. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
10. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
11. DJO Incorporated Announces Planned Transition of President and CEO Les Cross
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... for the second quarter ended June 30, 2015. ... both HETLIOZ and Fanapt" said Mihael H. Polymeropoulos M.D., ... and life cycle management of our products set the ...   Financial Highlights , Total net ...
(Date:7/29/2015)... , July 29, 2015 Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... on Monday, August 10, 2015 after the close of ... conference call and webcast on Monday, August 10, 2015 ... discuss the results and corporate developments. For ...
(Date:7/29/2015)... July 29, 2015  Depomed, Inc. (NASDAQ: DEPO ... its Board of Directors, after careful consideration and ... legal advisors, has unanimously rejected the purported revised, ... Pharma plc (NASDAQ: HZNP ) ("Horizon") to ... in an all-stock transaction (the "July 21 Proposal"). ...
Breaking Medicine Technology:Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 10Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 11Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 12Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 13Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 14Asterias Biotherapeutics to Report Second Quarter Results on August 10, 2015 2Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 2Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 3Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 4Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 5Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 6Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 7Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 8Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 9
... BOZEN, SUD-TIROL, Italy , July 27, 2010 ... assets from, Italy -based MEDarchiver S.r.l. and Biomedical Technology Consulting S.r.l.,merging ... market, and conducting a re-organization of its,Executive Management, expecting to close ... , , ...
... Sysmex America, Inc., a leading medical diagnostic ... to debut its expanded cell image analysis portfolio during ... Conference and Clinical Lab Expo July 25 - ... DM1200 and DM96 systems for the mid-size to larger ...
Cached Medicine Technology:Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies 2Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies 3Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies 4Sysmex America to Launch Complete Cell Image Analysis Portfolio at AACC 2Sysmex America to Launch Complete Cell Image Analysis Portfolio at AACC 3
(Date:7/29/2015)... ... ... According to The Spirits Business on July 16th, a new study ... perpetuating alcohol use disorders. Humans have the same gene, which is called Rsu1. The ... and has given researchers inklings to explore Rsu1 in humans to abate alcohol addiction ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... anticipating testing regulations imposed by the FDA for nicotine laced liquid products. Their ... electronic cigarettes have raised considerably. E-Cigarettes are particularly troublesome to addiction professionals as ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... Michigan, changed its name in July to Kalamazoo Strength & Conditioning. , The ... , and “reflects the evolution of our training center over the past three ...
(Date:7/29/2015)... , ... July 29, 2015 , ... San Fernando ... on Ultherapy. For a limited time only, patients can get the complete treatment process ... for patients who prefer a non-invasive treatment and have loose or sagging skin. ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... For the ... to be featured in the list of the 50 fastest growing companies in Jacksonville. ... around the business community. On July 16th, a team of Vast Bridges staffers were ...
Breaking Medicine News(10 mins):Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 2Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:San Fernando Valley Dermatology Office, Castle Dermatology Institute, is Now Offering a Promotional Price on Ultherapy 2Health News:Vast Bridges Continues Its Swift Growth 2
... , , , TAMPA, Fla., ... and Americans are more health-conscious than they,ve ever been before. As ... a good thing, the combination of an aging population and new ... professionals. Healthcare credentials at any level -- from one-year ...
... September 1, 2009Patients with advanced illnesses more than doubled ... health plan made hospice care more readily accessible, according ... Journal of Palliative Medicine , a peer-reviewed publication ... of Palliative Medicine is the official journal of ...
... promise in the treatment of a myriad of diseases, ... However, developing a scalable system for delivering genes to ... Now a team of Northwestern University researchers has introduced ... technology that combines key properties in one approach: enhanced ...
... , CHICAGO, Sept. 1 Today Jack ... new online video series, called " Living Positive By Design : ... education initiative. The Living Positive By Design campaign, supported ... thoughtful conversations about HIV and AIDS, to confront HIV stigma and ...
... AMR Research , the leading research firm focused on ... announce that Hussain Mooraj, vice president and head of healthcare and ... of the 100 most inspiring people in the life sciences industry. ... edition, "One of the most knowledgeable individuals in the healthcare arena, ...
... , CINCINNATI, Sept. 1 ... of physician office-based patient-education programs has announced that SIGVARIS, ... is expanding to the Skin Care Network to broaden ... dermatologist,s office is an ideal place to increase the ...
Cached Medicine News:Health News:Saving Lives Is a Growth Industry 2Health News:Saving Lives Is a Growth Industry 3Health News:Expanded insurance benefits break down barriers to hospice care, according to new study 2Health News:Promise of nanodiamonds for safer gene therapy 2Health News:Promise of nanodiamonds for safer gene therapy 3Health News:Video: 'Project Runway' Designer Launches New Online Video Series to Educate About Living with HIV and AIDS and Help Combat HIV Stigma 2Health News:Video: 'Project Runway' Designer Launches New Online Video Series to Educate About Living with HIV and AIDS and Help Combat HIV Stigma 3Health News:AMR Research Analyst Named One of the Most Inspiring Individuals in Life Sciences by PharmaVOICE 2Health News:AMR Research Analyst Named One of the Most Inspiring Individuals in Life Sciences by PharmaVOICE 3Health News:SIGVARIS USA Extends Educational Efforts in Healthy Advice's Skin Care Network 2Health News:SIGVARIS USA Extends Educational Efforts in Healthy Advice's Skin Care Network 3
Graether Collar Button micro iris retractor....
... Boston simplus multi-action solution is the first ... not only cleans, disinfects and conditions gas ... daily, with cleaning comparable to the leading ... cushioning system provides comfort upon insertion by ...
Fluoroperm 151 lens meets special needs of certain patients who need exceptional oxygen permeability for specific corneal condition or lifestyle requirements....
... a simultaneous vision lens with ... a series of front and ... Gp delivers up to +3.00 ... multi-aspheric center-distance design works in ...
Medicine Products: